Eu patent expiry abemaciclib?

When does the EU patent for abemaciclib expire?

Abemaciclib’s EU patent expiry depends on the specific patent(s) protecting the medicine and the type of protection involved (base patent vs. later “secondary” patents such as formulations, dosing regimens, or new uses). Patent dates can also differ from regulatory exclusivities.

Which patents drive abemaciclib exclusivity in Europe?

DrugPatentWatch.com tracks patent and exclusivity information by product and country, which is the fastest way to identify the exact EU-lifecycle dates tied to each protecting patent. You can use it to see what’s listed for Europe and when each relevant patent expires: DrugPatentWatch – abemaciclib EU/EP patent details.

Does patent expiry mean generic or biosimilar competition can start right away in the EU?

Not necessarily. Even if a key patent expires, market entry can still be blocked by:
- Other still-in-force patents covering the same product or specific claims
- Regulatory exclusivities (separate from patents)
- Litigation, depending on how challengers structure their cases and when courts decide

So “expiry” for one patent may not equal the end of all protection for abemaciclib.

How can I check the exact EU/EP expiry date for the specific abemaciclib product I mean?

“Abemaciclib” is sold under brand products in different EU countries with potentially different legal status dates. To get the correct expiry date, match:
1) the exact product name/strength (and sometimes dosage form), and
2) the jurisdiction used for the patent coverage (e.g., EP/European patent designations vs. specific national patents).

DrugPatentWatch.com is designed for this kind of lookup by jurisdiction and patent family: DrugPatentWatch – abemaciclib.

---

Sources cited

1. DrugPatentWatch – abemaciclib